Quotes 5-day view Delayed Nasdaq
01/14/2021
01/15/2021
01/19/2021
01/20/2021
01/21/2021
Date
6.22(c)
6.13(c)
6.115(c)
6.16(c)
6.06 Last
1 081 758
614 123
819 530
1 170 743
568 315 Volume
+2.47% -1.45% -0.24% +0.74% -1.62% Change
Sales 2020
82,0 M - -
Net income 2020
-53,7 M - -
Net Debt 2020
-
-
-
P/E ratio 2020
-3,96x
Yield 2020
-
Sales 2021
14,0 M - -
Net income 2021
-124 M - -
Net Debt 2021
-
-
-
P/E ratio 2021
-1,75x
Yield 2021
-
Capitalization
203 M 203 M -
Capi. / Sales 2020
2,48x
Capi. / Sales 2021
14,5x
Nbr of Employees
140
Free-Float
88,6%
Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules...
Notations Surperformance© of Assembly Biosciences, Inc.
Trading Rating : Investor Rating :
All news about ASSEMBLY BIOSCIENCES, INC.
2020 ASSEMBLY BIOSCIENCES : Jefferies Adjusts Price Target for Assembly Biosciences t..MT
2020 Assembly Biosciences To End Microbiome Program, Focuses on Hepatitis B Virus .. MT
2020 ASSEMBLY BIOSCIENCES, INC. : Costs Associated with Exit or Disposal Activities, ..AQ
2020 Assembly Biosciences to Wind-Down Microbiome Program GL
2020 Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635.. GL
2020 Mizuho Adjusts Assembly Biosciences' PT to $13 From $30 After H0731 'Failure .. MT
2020 ASSEMBLY BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (fo..AQ
2020 ASSEMBLY BIOSCIENCES : Appoints Nicole S. White, PhD, as Senior Vice President o..AQ
2020 Assembly Biosciences Appoints Nicole S. White, PhD, as Senior Vice President .. GL
2020 Assembly Biosciences, Door Pharmaceuticals Team Up On Developing HBV Core Pro.. MT
2020 ASSEMBLY BIOSCIENCES : and Door Pharmaceuticals Sign Collaboration and Option Ag..AQ
2020 Assembly Biosciences and Door Pharmaceuticals Sign Collaboration and Option A.. GL
2020 Assembly Biosciences Presents Data from HBV Core Inhibitor Programs in Poster.. GL
2020 ASSEMBLY BIOSCIENCES : Presents Data from HBV Core Inhibitor Programs in Poster ..AQ
2020 ASSEMBLY BIOSCIENCES : Reports Inducement Grant Under Nasdaq Listing Rule 5635(c..AQ
News in other languages on ASSEMBLY BIOSCIENCES, INC.
- No features available -
Analyst Recommendations on ASSEMBLY BIOSCIENCES, INC.
Chart ASSEMBLY BIOSCIENCES, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ASSEMBLY BIOSCIENCES, INC.
Short Term Mid-Term Long Term Trends Neutral Bearish Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
6
Average target price
18,60 $
Last Close Price
6,16 $
Spread / Highest target
631%
Spread / Average Target
202%
Spread / Lowest Target
13,6%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
